#United States #financial results #Canton #Kelyniam Global #Osteopore Ltd

Kelyniam Global's Q1 2025 Financial Results and Strategic Expansion

On May 12, 2025, Kelyniam Global, Inc. (OTC: KLYG), a prominent manufacturer specializing in custom cranial and craniofacial implants, unveiled its financial outcomes for the first quarter ending March 31, 2025. This period showed a noteworthy decrease in revenue, alongside the announcement of a significant partnership aimed at bolstering future growth.

Financial Highlights of Q1 2025

Comparing to the same quarter last year, Kelyniam reported a total revenue of $624,910, reflecting a substantial decline of 34.7% from $957,447 in Q1 2024. The gross margin similarly saw a decrease, reported at $470,940, a 36.6% drop from $743,719 in the previous year. Furthermore, the company faced an operating loss of $(140,556), contrasting with an operating profit of $123,599 last year.

Ross Bjella, the CEO of Kelyniam, attributed these financial challenges to seasonal fluctuations and timing issues with surgical schedules, which resulted in delayed revenue recognition. In response to these hurdles, Kelyniam has made strategic changes, including the appointment of Alex Rivero as National Sales Director and plans to onboard an additional ten distributors throughout 2025. The firm emphasizes its commitment to delivering custom implants within a rapid 24 to 48 hours, positioning itself well for improved performance through these initiatives.

Strategic Partnerships

In a strategic move to enhance its market presence, Kelyniam has formed a three-year distribution agreement with Osteopore Ltd., a medical technology firm based in Singapore that specializes in regenerative implants. Through this partnership, Kelyniam is set to distribute Osteopore’s bioresorbable products such as Osteostrip®, Osteoplug®, and Osteomesh® in the United States, providing advanced solutions for cranial bone regeneration.

Bjella stated, "Our alliances with Osteopore and Finceramica not only position Kelyniam as a leader in regenerative medicine in the U.S. but also underscore our commitment to quality service. Regenerative products are crucial to the future of cranial surgery and will give Kelyniam a unique market advantage alongside our dedication to excellence."

Desiree Webb, Kelyniam's Chief Operating and Revenue Officer, highlighted the need for biomimetic and bioresorbable options for surgeons seeking optimal natural bone growth. She expressed confidence that Kelyniam’s high level of service, coupled with Osteopore’s innovative products, will lead to significant advancements in the field of cranial and craniofacial regenerative options.

Osteopore’s CEO, Dr. Yujing Lim, praised Kelyniam’s proven track record in manufacturing and distribution, noting that partnering directly with Kelyniam could accelerate market access to Osteopore's cutting-edge products due to their established connections within the hospital sector.

Looking Ahead

Kelyniam plans to share further details about its financial results and strategic directions during its Annual Shareholder Meeting scheduled for June 23, 2025, at 9:00 AM Central Time. Investors can access complete financial results at Kelyniam’s official website.

About Kelyniam Global, Inc.

Kelyniam specializes in the design, manufacture, and distribution of custom cranial and craniofacial implants using biocompatible materials. The company is renowned for its ability to deliver products rapidly, ensuring collaboration with medical professionals to enhance clinical outcomes. To learn more, visit www.kelyniam.com.

About Osteopore Ltd.

Osteopore, listed on the Australian Securities Exchange, develops innovative bioresorbable scaffolds for bone regeneration utilizing advanced 3D printing technology aimed at promoting natural healing across various medical applications.

About Finceramica Faenza S.p.A.

Finceramica, located in Faenza, Italy, specializes in biomimetic biomaterials recognized for their applications in medical use, particularly known for low infection rates in cranial reconstruction.

This press release also contains forward-looking statements as defined under applicable securities laws, including insights into projected future sales and distributor expansion, which may carry inherent risks and uncertainties that might cause actual results to diverge from expectations. Kelyniam does not commit to updating these statements except when legally required.